Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

124
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
124
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

106
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
106
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

229
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
229
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

147
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
147
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

690
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
690
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

377
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
377

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid personalisation of cardiovascular models using invasively measured right ventricular pressure.

Computers in biology and medicine·2026
Same author

Artificial intelligence-enabled histological analysis in pre-clinical respiratory disease models: a scoping review.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis.

Stem cells translational medicine·2026
Same author

Regulatory T-cell based therapies for acute lung injury: a systematic review and meta-analysis.

American journal of respiratory cell and molecular biology·2026
Same author

Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.

Science translational medicine·2026
Same author

Digital twins for cardiopulmonary medicine: the case for pulmonary arterial hypertension.

American journal of respiratory and critical care medicine·2026
Same journal

Printing the future of surgical education: a randomized trial of digital tools in cardiovascular training.

Cardiovascular diagnosis and therapy·2026
Same journal

A narrative review on the use of artificial intelligence in cardiovascular medicine.

Cardiovascular diagnosis and therapy·2026
Same journal

Association of neutrophil to lymphocyte ratio with the severity of coronary artery lesions in patients undergoing coronary angiography for the first time.

Cardiovascular diagnosis and therapy·2026
Same journal

Certain role of extra-domain A containing fibronectin in the development of pulmonary hypertension in the sugen/hypoxia mouse model.

Cardiovascular diagnosis and therapy·2026
Same journal

Electrocardiographic changes in immune checkpoint inhibitor-associated cardiac injury: a narrative review.

Cardiovascular diagnosis and therapy·2026
Same journal

Automated right ventricle-to-left ventricle diameter ratio predicts ICU stay for acute pulmonary embolism on CTPA examinations in the emergency department.

Cardiovascular diagnosis and therapy·2026
See all related articles

Related Experiment Video

Updated: Nov 29, 2025

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

528

Emerging therapies for right ventricular dysfunction and failure.

Anna Klinke1, Torben Schubert1, Marion Müller1

  • 1Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.

Cardiovascular Diagnosis and Therapy
|November 23, 2020
PubMed
Summary
This summary is machine-generated.

Therapeutic options for right ventricular failure are limited. Novel approaches targeting metabolism, RNA, cells, and pulmonary denervation show promise for treating right heart failure, particularly in pulmonary arterial hypertension.

Keywords:
Right ventriclepulmonary arterial hypertension (PAH)remodelingright heart failure (RHF)right heart failure therapy

More Related Videos

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.9K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.7K

Related Experiment Videos

Last Updated: Nov 29, 2025

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

528
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.9K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.7K

Area of Science:

  • Cardiology and Pulmonary Medicine

Background:

  • Therapeutic options for right ventricular (RV) dysfunction and failure remain limited.
  • Right heart failure (RHF) is often studied within the context of pulmonary arterial hypertension (PAH), complicating the distinction between pulmonary vascular and RV-specific effects of treatments.
  • Opposing pathomechanisms in the RV and pulmonary vasculature hinder effective RHF management in PAH.

Purpose of the Study:

  • To review current pharmacological, RNA-based, and cell-based therapeutic strategies for RV dysfunction.
  • To evaluate the potential of these therapies to directly target the RV.
  • To review data on pulmonary artery denervation and mechanical circulatory support for RHF.

Main Methods:

  • Review of experimental studies in animal models of PAH and RV dysfunction.
  • Analysis of pre-clinical data on novel pharmacological agents, microRNA (miRNA) and long non-coding RNA (lncRNA) strategies, and cell-based therapies.
  • Examination of data on pulmonary artery denervation and mechanical circulatory support.

Main Results:

  • Novel agents modulating metabolism, reactive oxygen species, and inflammation show promise.
  • Established PAH therapies like PDE-5 inhibitors and sGC stimulators may directly benefit the RV.
  • RNA-based strategies (miRNA, lncRNA) and cell-based therapies demonstrate potential for RV remodeling and microvascular improvement.
  • Pulmonary artery denervation and mechanical circulatory support are emerging options.

Conclusions:

  • Directly targeting the RV with novel pharmacological, RNA-based, and cell-based therapies offers new hope for RHF.
  • Pulmonary artery denervation and mechanical circulatory support represent alternative or adjunctive strategies.
  • Further research is needed to translate these promising pre-clinical findings into clinical success, particularly regarding cell delivery and the specific application of interventions in PAH-associated RHF.